Oxaliplatin‐induced immune pancytopenia

Behrouz Mansouri Taleghani(University of Bern), Abdulgabar Salama(Humboldt-Universität zu Berlin), Urban Novak(University of Bern), Stefano Fontana, Markus Borner(University of Bern), Norbert Ahrens(University Hospital Regensburg), Oliver Meyer(Université Claude Bernard Lyon 1)

Transfusion

April 6, 2005

10.1111/j.1537-2995.2005.04373.x

Cited by 65

Related Papers

Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials

|The Lancet|2020|445

Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome

|Blood|2010|189

High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel

|Annals of Oncology|2001|151

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

|The Lancet|2024|135

Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK

|Annals of Oncology|2008|129